fashion -WSS

fashion

author：comprehensive 2025-09-29 23:28:15 - browse：7654

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Amylyx ALS drug failure raises questions and concerns

focus

leisure time

WSS

What it’s like to watch children die of measles

Adele warns fans about throwing things at performers onstage

Sen. Paul opposes bill to ban Chinese biotechs

The Readout: Amylyx, Alumis, and Lundbeck drug updates

NEJM study link tiny plastics in blood vessels to heart problems

Air quality improving but still lags in Black, Hispanic communities

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

New air purifier tech could be key to improving indoor air quality

Former New York Mayor de Blasio and wife announce separation, but not divorce

Drug repurposing or repositioning? The language matters

Pentagon will tighten controls on classified information after Discord leak

FDA approval of Sarepta Duchenne genetic therapy gives me hope

In his State of the Union, Biden takes clear aim at 'Big Pharma'

The high cost of giving birth even with insurance

City of Memphis, police chief oppose effort to delay lawsuit in Tyre Nichols case

After affirmative action ruling, medical educators look to 'holistic review'

Man pleads guilty to raping Ohio girl who ended up traveling across state lines for abortion

hotspot

Ph.D. graduate surprised with gift registry: 'You deserve to be celebrated'

Change Healthcare payments predicted restored March 15

Sen. Paul opposes bill to ban Chinese biotechs

'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

Adele warns fans about throwing things at performers onstage

The Readout: Amylyx, Alumis, and Lundbeck drug updates

focus

focus

leisure time

explore